Apr 19,2017

Tandem Diabetes Care to Present at the Deutsche Bank 42nd Annual Health Care Conference

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today announced that Kim Blickenstaff, president and CEO, will present a company update at the Deutsche Bank 42nd Annual Health Care Conference in Boston, MA. The presentation will take place on Wednesday, May 3, 2017 at 8:40 AM Eastern Time (5:40 AM Pacific Time).

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Apr 23,2017

BD Announces Appointment of Tom Polen as President

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, announced today the appointment of Tom Polen, 43, as president of BD, effective immediately.

View Analyst & Ambassador Comments
Go to original news
Apr 24,2017

Ascensia Diabetes Care Announces Partnership with the Dr. Oz Show to Launch the 60-Day Diabetes Challenge

Ascensia Diabetes Care today announced it is partnering with The Dr. Oz Show to launch a 60-Day "Take Charge" Diabetes Challenge. Ascensia is sponsoring the challenge, which is designed to increase awareness of diabetes among the general public and help to encourage better management of the condition. It will launch during the April 26 episode of The Dr.Oz Show and focuses on the importance of testing blood glucose levels regularly and maintaining a healthy diet.

PRODUCT

#bgm

View Analyst & Ambassador Comments
Go to original news
Apr 24,2017

Nemaura Medical Inc. successfully completes development of second-generation sugarBEAT® non-invasive Continuous Glucose Monitoring skin-patch.

Nemaura Medical Inc. (OTCBB: NMRD), a medical device company has today announced the successful completion of the development and testing of its second-generation sugarBEAT® wireless skin-patch as a non-invasive, needle-free Continuous Glucose Monitoring (CGM) system for use by diabetics. The first-generation sugarBEAT® received CE approval in Q1 2016, as a wired wrist-watch based non-invasive, needle-free CGM system.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Apr 25,2017

1Drop Diagnostics and Massachusetts General Hospital Clinicians Collaborate on Next Generation Portable Medical Diagnostics

1Drop Diagnostics is working with clinicians at Massachusetts General Hospital to investigate a PoC device whose ease of use, high quality results and affordability would enable its use in a wide range of primary care settings, including clinics, nursing and rehabilitation homes, and pharmacies. The device, which would use blood from a finger stick instead of a phlebotomy blood draw, would save time and costs and would allow medical professionals to make informed decisions in a single office visit.

COLLABORATION PARTNERSHIP

#r&d

View Analyst & Ambassador Comments
Go to original news
Apr 26,2017

Brighter secures external financing of up to SEK 100 million to support the launch of Actiste® and issues free warrants to its shareholders

Brighter has signed an agreement relating to an investment of up to SEK 100 million. The capital will be used for the production and the launch of Actiste, the company's unique diabetes service. The transaction is carried out through a private placement of convertible notes with warrants attached in up to eight tranches spread over 36 months. The first Tranche issued by Brighter amounts to SEK 30 million.

View Analyst & Ambassador Comments
Go to original news
Apr 27,2017

Tandem Diabetes Care Reports First Quarter 2017 Financial Results

Tandem Diabetes Care®, Inc. (NASDAQ: TNDM), a medical device company and manufacturer of the only touchscreen insulin pumps available in the United States, today reported its financial results for the quarter ended March 31, 2017. A total of 2,816 pumps were shipped in the quarter, down 30% from the 4,042 pumps shipped in the same period of 2016. GAAP sales declined 5 percent to $19.0 million for the quarter ended March 31, 2017 compared to $20.1 million for the same period of 2016.

View Analyst & Ambassador Comments
Go to original news
May 01,2017

Amalgam Rx gets FDA nod for insulin titration app

AmalgamRx, a newly unstealthed company founded by WellDoc founders Ryan Sysko and Dr. Suzanne Clough, has received FDA clearance for iSage, an insulin titration algorithm. iSage is a prescription-only patient-facing iOS and Android app that works in conjunction with a web portal used by the doctor. The doctor sets target levels for insulin based on the patient’s glucose levels. Then the algorithm takes over. Patients can enter their blood glucose levels and iSage will change their insulin dosing levels based on the doctor’s plan and the entered values.

REGULATORY FDA
View Analyst & Ambassador Comments
Go to original news
May 02,2017

Rimidi and Heritage Provider Network partnership expands to diabetes, congestive heart failure

Atlanta-based digital health company Rimidi has expanded its partnership with Heritage Provider Network to offer its digital disease management platform to people living with diabetes and congestive heart failure in the greater Palm Springs area. Desert Oasis Healthcare, which is part of Heritage Provider Network, will offer patients access to Rimidi's Diabetes + Me and CHF program to track and share health data with their care teams and get feedback and coaching.

COLLABORATION PARTNERSHIP

#product & service

#rpm

View Analyst & Ambassador Comments
Go to original news
May 09,2017

DreaMed, Harvard partner for research and development

Israeli diabetes management company DreaMed is working with researchers from Schneider Children’s Medical Center and the Harvard John A. Paulson School of Engineering and Applied Sciences (SEAS) to study insulin management in children with Type 1 diabetes who don’t use CGMs or insulin pumps. The goal is to understand the behavior patterns of these patients and to design a dosing support system that will help them better manage their condition.

COLLABORATION PARTNERSHIP

#r&d

#bgm

#insulin pen

View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES